Literature DB >> 31603370

Management of Athletes With G6PD Deficiency: Does Missing an Enzyme Mean Missing More Games?

Shane N Stone1, Karl V Reisig2, Heather L Saffel1, Christopher M Miles1.   

Abstract

CONTEXT: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is likely the most prevalent enzyme deficiency on the planet, with an estimated 4.9% of people, or approximately 330 million individuals, across the globe affected by the disease. In the United States, 4% to 7% of the population is likely affected, but each year our nation's major sport leagues become more international. It is important for medical professionals who treat athletes to understand how this genetic condition can affect the athletes we are working with, especially because exercise in itself results in oxidative stress. EVIDENCE ACQUISITION: PubMed was searched for relevant articles published from 1980 to 2018. The search terms G6PD, athletes, military, and sports were used. STUDY
DESIGN: Clinical review. LEVEL OF EVIDENCE: Level 4.
RESULTS: Though some case reports suggest a potential impact on athlete safety and performance, controlled studies demonstrate limited impact of exercise on oxidative stress in G6PD-deficient individuals. The care of athletes with G6PD deficiency does not drastically differ from the care of athletes without this condition. Most of the medications and supplements that are regularly given to athletes should not negatively affect their health.
CONCLUSION: Although the care of athletes with G6PD deficiency is for the most part no different from the care of other athletes, there are certain situations (visiting areas where malaria is endemic) and medications for which it is important to recognize how your management should change. G6PD deficiency is not regularly screened for but could be considered if an athlete has known sickle cell disease or when traveling to areas where malaria is prevalent. Expanding our knowledge of G6PD deficiency will allow for better care of athletes.

Entities:  

Keywords:  G6PD deficiency; athlete; international; medication safety; supplements

Mesh:

Substances:

Year:  2019        PMID: 31603370      PMCID: PMC7040941          DOI: 10.1177/1941738119877177

Source DB:  PubMed          Journal:  Sports Health        ISSN: 1941-0921            Impact factor:   3.843


  25 in total

1.  Rhabdomyolysis and hemolysis associated with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency.

Authors:  G Kimmick; J Owen
Journal:  South Med J       Date:  1996-11       Impact factor: 0.954

Review 2.  Use of prescription drugs in athletes.

Authors:  Antti Alaranta; Hannu Alaranta; Ilkka Helenius
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

3.  Possible incompatibility of glucose-6-phosphate dehydrogenase deficiency and championship athletic performance.

Authors:  N L Petrakis; S J Petrakis; S L Wiesenfeld; E Spanidou
Journal:  Med Sci Sports       Date:  1974

Review 4.  Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review.

Authors:  Shaun Wen Huey Lee; Nai Ming Lai; Nathorn Chaiyakunapruk; David Weng Kwai Chong
Journal:  Br J Clin Pharmacol       Date:  2016-05-21       Impact factor: 4.335

5.  L-cysteine supplementation protects the erythrocyte glucose-6-phosphate dehydrogenase activity from reduction induced by forced training.

Authors:  Kleopatra H Schulpis; George J Reclos; Theodore Parthimos; Nickolaos Parthimos; Andreas Gavriilidis; Stylianos Tsakiris
Journal:  Clin Biochem       Date:  2006-07-12       Impact factor: 3.281

Review 6.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

Authors:  Ella T Nkhoma; Charles Poole; Vani Vannappagari; Susan A Hall; Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2009-02-23       Impact factor: 3.039

7.  Muscle expression of glucose-6-phosphate dehydrogenase deficiency in different variants.

Authors:  P Ninfali; L Baronciani; A Bardoni; N Bresolin
Journal:  Clin Genet       Date:  1995-11       Impact factor: 4.438

Review 8.  Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.

Authors:  Ilan Youngster; Lidia Arcavi; Renata Schechmaster; Yulia Akayzen; Hen Popliski; Janna Shimonov; Svetlana Beig; Matitiahu Berkovitch
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.228

9.  New Diagnosis of G6PD Deficiency Presenting as Severe Rhabdomyolysis.

Authors:  Akaolisa S Eziokwu; Dana Angelini
Journal:  Cureus       Date:  2018-03-28

Review 10.  G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.

Authors:  Lucio Luzzatto; Elisa Seneca
Journal:  Br J Haematol       Date:  2013-12-28       Impact factor: 6.998

View more
  1 in total

1.  Acute Hepatitis A Causing Severe Hemolysis and Renal Failure in Undiagnosed Glucose-6-Phosphate Dehydrogenase Deficient Patient: A Case Report and Review of the Literature.

Authors:  Iman Abutineh; Kyle Kreitman; Jiten P Kothadia; Bilal Ali; Richa Jain; Ian Clark; Benedict J Maliakkal; Satheesh P Nair
Journal:  Case Reports Hepatol       Date:  2021-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.